Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding - Nagakura, T; Tabata, K; Kira, K (Thromb Res, 2013)
et al.